#United States #Cambridge #ALS #TDP-43 #NeuroSense Therapeutics

NeuroSense's Breakthrough in ALS Research

NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company based in Cambridge, Massachusetts, is making significant strides in the fight against amyotrophic lateral sclerosis (ALS). The company has recently announced successful results from its Phase 2b PARADIGM study, indicating a noteworthy reduction in TDP-43 levels among ALS patients treated with PrimeC compared to a placebo group. This study marks a pivotal point in the ongoing effort to combat this devastating disease, which significantly impacts those diagnosed.

What is TDP-43?

TDP-43 is a protein associated with various neurodegenerative diseases, including ALS. Present in over 97% of all ALS cases, it is recognized as a major contributor to the progression of the disease. The Phase 2b study is particularly significant as it represents the first randomized, placebo-controlled trial demonstrating a treatment-related reduction in TDP-43 levels in individuals living with ALS.

Study Highlights

The PARADIGM study focused on the safety and efficacy of PrimeC, a novel oral drug candidate designed to target multiple pathways that underlie the progression of ALS. The trial utilized a unique method known as the NeuroDex ExoSORT procedure, which isolates neuron-derived extracellular vesicles (NDEs) to measure TDP-43 levels accurately.

At the designated primary endpoint of 180 days, the data revealed a statistically significant reduction in TDP-43 levels in patients receiving PrimeC (p=0.0421) compared to those on placebo. Remarkably, this effect not only persisted but was further deepened over the subsequent 18 months, with participants continuing to show lower TDP-43 levels at 540 days (p<0.001).

Previously released outcomes from the PARADIGM study demonstrated additional promising results, including an impressive 15-month median survival benefit (HR 0.35, p=0.004) and a significant slowdown in the ALS Functional Rating Scale (ALSFRS-R) decline at both 12 and 18 months (36.5%, p=0.008, and 32.8%, p=0.007, respectively).

Implications of the Findings

The results were met with enthusiasm by key figures in the ALS research community. Alon Ben-Noon, CEO of NeuroSense, emphasized that achieving the primary endpoint in this study represents a transformative moment in ALS research, particularly given the elusive nature of demonstrating a treatment-related reduction in TDP-43. He highlighted that these findings validate PrimeC's role as a potential disease-modifying therapy.

In support of these statements, Prof. Merit Cudkowicz, a well-respected neurologist at Harvard Medical School, remarked on the importance of the TDP-43 findings, indicating that they suggest a genuine engagement with a pathological process shared among most ALS patients. Coupled with previously reported data on safety and biomarkers, the study's outcomes bolster the case for progressing to Phase 3 clinical trials.

What’s Next for NeuroSense?

Following these favorable results, NeuroSense has received FDA clearance to initiate a global Phase 3 study, named PARAGON, which aims to enroll around 300 participants, primarily in the United States. The anticipation surrounding this next phase signifies hope for patients and families affected by ALS, as well as an ambitious step forward in the realm of neurodegenerative disease treatment.

In conclusion, NeuroSense Therapeutics is positioning itself as a leader in ALS treatment advancements, with strong clinical evidence supporting its approach. As the company progresses into the next phase of clinical trials, the ALS community is hopeful for new avenues of treatment that could significantly alter patients' lives.

About NeuroSense

NeuroSense Therapeutics focuses on developing innovative treatments targeting severe neurodegenerative diseases, such as ALS and Alzheimer’s. The lead candidate, PrimeC, utilizes a unique formulation that targets several biological pathways involved in disease progression, including neuroinflammation and oxidative stress.

As the ALS community awaits the outcomes of the upcoming Phase 3 trials, NeuroSense continues to advocate for ongoing research and commitment to improving patient care in the field of neurodegenerative diseases.